BACKGROUND: Infections are an important cause of morbidity and mortality for acute lymphoblastic leukemia (ALL). However, the reports regarding risk factors of induction-related infection are roughly unknown/limited in adult T-ALL during induction chemotherapy. METHODS: We performed a retrospective cohort study for the prevalence and risk predictors of induction-related infection among consecutive T-ALL patients (N = 97) enrolled in a PDT-ALL-LBL clinical trial. Of 97 patients with T-ALL enrolled in the trial, 46 were early T-cell precursor (ETP) ALL and 51 were non-ETP ALL. RESULTS: When compared with non-ETP, ETP ALL subtype was characterized with lower neutrophil count (1.35 × 109/L vs. 8.7 × 109/L, P < 0.001) and lower myeloid percentage in the bone marrow (13.35% vs. 35.31%, P = 0.007). Additionally, ETP ALL had longer neutropenia before diagnosis (P < 0.001), as well as during induction chemotherapy (P < 0.001). Notably, the ETP cohort experienced higher cumulative incidence of clinically documented infections (CDI; 33.33%, P = 0.001), microbiologically documented infections (MDI; 45.24%, P = 0.006), resistant infection (11.9%, P = 0.013), and mixed infection (21.43%, P = 0.003), respectively, than those of the non-ETP cohort. Furthermore, multivariable analysis revealed that T-ALL mixed infection was more likely related to chemotherapy response (OR, 0.025; 95% CI 0.127-0.64; P = 0.012) and identified myeloid percentage as a predictor associated with ETP-ALL mixed infection (OR, 0.915; 95% CI 0.843-0.993; P = 0.033), with ROC-defined cut-off value of 2.24% in ETP cohorts. CONCLUSIONS: Our data for the first time demonstrated that ETP-ALL characterized with impaired myelopoiesis were more susceptible to induction-related infection among T-ALL populations.
BACKGROUND: Infections are an important cause of morbidity and mortality for acute lymphoblastic leukemia (ALL). However, the reports regarding risk factors of induction-related infection are roughly unknown/limited in adult T-ALL during induction chemotherapy. METHODS: We performed a retrospective cohort study for the prevalence and risk predictors of induction-related infection among consecutive T-ALL patients (N = 97) enrolled in a PDT-ALL-LBL clinical trial. Of 97 patients with T-ALL enrolled in the trial, 46 were early T-cell precursor (ETP) ALL and 51 were non-ETP ALL. RESULTS: When compared with non-ETP, ETP ALL subtype was characterized with lower neutrophil count (1.35 × 109/L vs. 8.7 × 109/L, P < 0.001) and lower myeloid percentage in the bone marrow (13.35% vs. 35.31%, P = 0.007). Additionally, ETP ALL had longer neutropenia before diagnosis (P < 0.001), as well as during induction chemotherapy (P < 0.001). Notably, the ETP cohort experienced higher cumulative incidence of clinically documented infections (CDI; 33.33%, P = 0.001), microbiologically documented infections (MDI; 45.24%, P = 0.006), resistant infection (11.9%, P = 0.013), and mixed infection (21.43%, P = 0.003), respectively, than those of the non-ETP cohort. Furthermore, multivariable analysis revealed that T-ALL mixed infection was more likely related to chemotherapy response (OR, 0.025; 95% CI 0.127-0.64; P = 0.012) and identified myeloid percentage as a predictor associated with ETP-ALL mixed infection (OR, 0.915; 95% CI 0.843-0.993; P = 0.033), with ROC-defined cut-off value of 2.24% in ETP cohorts. CONCLUSIONS: Our data for the first time demonstrated that ETP-ALL characterized with impaired myelopoiesis were more susceptible to induction-related infection among T-ALL populations.
Authors: Shannon L Maude; Sibasish Dolai; Cristina Delgado-Martin; Tiffaney Vincent; Alissa Robbins; Arthavan Selvanathan; Theresa Ryan; Junior Hall; Andrew C Wood; Sarah K Tasian; Stephen P Hunger; Mignon L Loh; Charles G Mullighan; Brent L Wood; Michelle L Hermiston; Stephan A Grupp; Richard B Lock; David T Teachey Journal: Blood Date: 2015-02-02 Impact factor: 22.113
Authors: Martin Neumann; Sandra Heesch; Cornelia Schlee; Stefan Schwartz; Nicola Gökbuget; Dieter Hoelzer; Nikola P Konstandin; Bianka Ksienzyk; Sebastian Vosberg; Alexander Graf; Stefan Krebs; Helmut Blum; Thorsten Raff; Monika Brüggemann; Wolf-Karsten Hofmann; Jochen Hecht; Stefan K Bohlander; Philipp A Greif; Claudia D Baldus Journal: Blood Date: 2013-04-19 Impact factor: 22.113
Authors: M Neumann; S Heesch; N Gökbuget; S Schwartz; C Schlee; O Benlasfer; N Farhadi-Sartangi; J Thibaut; T Burmeister; D Hoelzer; W-K Hofmann; E Thiel; C D Baldus Journal: Blood Cancer J Date: 2012-01-27 Impact factor: 11.037
Authors: Louise M Treanor; Sheng Zhou; Laura Janke; Michelle L Churchman; Zhijun Ma; Taihe Lu; Shann-Ching Chen; Charles G Mullighan; Brian P Sorrentino Journal: J Exp Med Date: 2014-03-31 Impact factor: 14.307
Authors: Han-Zhou Qi; Jun Xu; Qian-Qian Yang; Ren Lin; Zhi-Xiang Wang; Ke Zhao; Qiang Wang; Xuan Zhou; Zhi-Ping Fan; Fen Huang; Na Xu; Li Xuan; Hua Jin; Jing Sun; Robert Peter Gale; Hong-Sheng Zhou; Qi-Fa Liu Journal: Bone Marrow Transplant Date: 2022-08-30 Impact factor: 5.174